| Aug 27 |
AptarGroup Hits 52-Week High: What's Driving the Stock's Performance?
|
| Aug 16 |
AptarGroup, Inc.'s (NYSE:ATR) Stock Has Fared Decently: Is the Market Following Strong Financials?
|
| Aug 15 |
Aptar’s Nasal Unidose System to Deliver neffy® (epinephrine nasal spray), the First and Only FDA-Approved Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
|
| Aug 14 |
Insider Sale: Director Monnas Kampouri Sells Shares of AptarGroup Inc (ATR)
|
| Aug 5 |
Chart advisor: Bitcoin: Yesterday, Today, and Tomorrow
|
| Jul 31 |
O-I Glass (OI) Tops Q2 Earnings Estimates, Lowers '24 Outlook
|
| Jul 31 |
AptarGroup, Inc. (NYSE:ATR) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
|
| Jul 27 |
AptarGroup Second Quarter 2024 Earnings: Revenues Disappoint
|
| Jul 26 |
AptarGroup (ATR) Earnings Beat Estimates in Q2, Increase Y/Y
|
| Jul 26 |
AptarGroup, Inc. (ATR) Q2 2024 Earnings Call Transcript
|
